A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma

4Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially in older patients. Substituting doxorubicin with non-PEGylated liposomal doxorubicin (R-COMP) may reduce the risk of cardiac events, but its efficacy has never been demonstrated in prospective trials. We describe the characteristics and outcome of patients with DLBCL aged ≥65 years prospectively enrolled in the Elderly Project by the Fondazione Italiana Linfomi and treated with full doses of R-CHOP or R-COMP per local practice. Starting from 1163 patients, 383 (55%) were treated with R-CHOP and 308 (45%) with R-COMP. Patients treated with R-COMP were older (median age, 76 vs 71 years), less frequently fit at simplified geriatric assessment (61% vs 88%; P < .001), and had a more frequent baseline cardiac disorders (grade >1, 32% vs 8%; P < .001). Three-year progression-free survival (PFS) was similar between R-CHOP and R-COMP (70% and 64%); 3-year overall survival was 77%, and 71% respectively. R-CHOP was associated with better PFS vs R-COMP only in the Elderly Prognostic Index (EPI) low-risk group. The two groups had similar rates of treatment interruptions due to toxicities or of cardiac events (P = 1.00). We suggest R-COMP is a potentially curative treatment for older patients with intermediate- or high-risk EPI, even in the presence of a baseline cardiopathy. R-CHOP is confirmed as the standard therapy for low risk patients.

References Powered by Scopus

Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma

4840Citations
N/AReaders
Get full text

Risk factors for doxorubicin-induced congestive heart failure

2175Citations
N/AReaders
Get full text

Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

1918Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology

1Citations
N/AReaders
Get full text

Diffuse large B-cell lymphoma with heart involvement: The relevance of the multidisciplinary and multiparameter approach

0Citations
N/AReaders
Get full text

Curative intent therapy for DLBCL in the elderly

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Arcari, A., Rigacci, L., Tucci, A., Puccini, B., Usai, S. V., Cavallo, F., … Merli, F. (2023). A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma. Blood Advances, 7(15), 4160–4169. https://doi.org/10.1182/bloodadvances.2023009839

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

71%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Nursing and Health Professions 1

14%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 22

Save time finding and organizing research with Mendeley

Sign up for free